Biosimilars Pharma Companies Regulations 
Drug Target Review
JUNE 16, 2025
All these features make GPCRs central to regulating many vital biological processes in the body, including immune responses and inflammation, and thus especially attractive for therapeutic intervention.
Drug Patent Watch
APRIL 8, 2025
"5 Key Considerations for Valuing Pharma Companies As the pharmaceutical industry continues to evolve, accurately valuing pharma companies has become increasingly complex. Patent Portfolio Strength : A strong patent portfolio can significantly impact a company's valuation.
The Pharma Data
JUNE 6, 2025
As pharma companies grapple with mounting pressure from regulators, payers, and evolving market dynamics, the CSO model offers a compelling alternative to traditional, fully in-house sales forces. Biosimilars and Generics : Where cost competition necessitates strategic brand differentiation and efficient coverage.
Expert insights. Personalized for you.
Let's personalize your content